proxyvotesnow.com

Home › Companies › IOVANCE BIOTHERAPEUTICS INC. › 2024-2025

IOVANCE BIOTHERAPEUTICS INC. 2024-2025 Proxy Voting Records

Compiled from SEC Form N-PX filings and IOVANCE BIOTHERAPEUTICS INC.’s Form 8-K, filed 2025-06-10 (Item 5.07 on EDGAR). Page generated 04 October 2026.

  • 14Reported items
  • 270Asset managers
  • 2,323Fund votes
  • 2025-06-10Meeting date

Proxy season: 2023-2024 2024-2025 2025-2026

Explore IOVANCE BIOTHERAPEUTICS INC. in the interactive database Compare manager voting policies

Official 2024-2025 meeting results reported by IOVANCE BIOTHERAPEUTICS INC.

These tallies are IOVANCE BIOTHERAPEUTICS INC.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed 2025-06-10 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.

IOVANCE BIOTHERAPEUTICS INC. — official shareholder meeting results, meeting held 2025-06-10
Ballot itemForAgainst AbstainWithheldBroker non-votesOutcome
Elect Director: Dr. Dukes 142,089,79530,706,3931,322,491 --80,162,659 Majority: yes
Elect Director: Dr. Countouriotis 97,767,91775,070,0201,280,742 --80,162,659 Majority: yes
Elect Director: Mr. Maynard 166,367,8696,453,5381,297,272 --80,162,659 Majority: yes
Elect Director: Mr. Rothbaum 166,890,3796,038,2841,190,016 --80,162,659 Majority: yes
Elect Director: Dr. Vogt 165,079,1378,467,205572,337 --80,162,659 Majority: yes
Elect Director: Dr. Weiser 165,295,5357,540,9401,282,204 --80,162,659 Majority: yes
Elect Director: Ms. Yarno 166,781,3245,674,4321,662,923 --80,162,659 Majority: yes

Source: IOVANCE BIOTHERAPEUTICS INC., Form 8-K, filed with the SEC on 2025-06-10 — read the filing on EDGAR.

How asset managers voted at the IOVANCE BIOTHERAPEUTICS INC. 2024-2025 meeting

Each item below shows how the 270 asset managers that disclosed a IOVANCE BIOTHERAPEUTICS INC. vote in their SEC Form N-PX filings actually voted. Share totals are the shares those managers' funds voted, summed across every fund they report. These are reported items, not a count of the ballot: fund filings describe one ballot item in different words. Two descriptions are shown as one item only on evidence — the same text (or one cut short of the other), the same director nominee, or a match to the same row of IOVANCE BIOTHERAPEUTICS INC.’s own Form 8-K tally — never because they merely read alike. A description that could not be joined that way is listed on its own, so one ballot item can appear more than once.

1. To approve, by non-binding advisory vote, the compensation of our named executive officers;

SECTION 14A SAY-ON-PAY VOTES

Meeting held 2025-06-10.

Combines 10 wordings of this item as funds reported it.

97% fund support · no official result

FOR 96%

The 258 asset managers below cast 97% of the shares they voted on this item FOR (128,735,602 for, 4,471,949 against).

FOR: 128,735,602 (96.4%)AGAINST: 4,471,949 (3.3%)ABSTAIN: 188,398 (0.1%)NOT VOTED: 129,705 (0.1%)
Largest asset managers voting on “To approve, by non-binding advisory vote, the compensation of our named executive officers;” at IOVANCE BIOTHERAPEUTICS INC., 2024-2025
Asset managerForAgainst AbstainWithheldVote
Vanguard28,614,5452,228 00For
MHR FUND MANAGEMENT LLC24,417,1030 00For
BlackRock13,185,80443,272 00For
Invenomic Capital Management LP6,574,3990 00For
T. Rowe Price5,844,1870 00For
MACQUARIE INVESTMENT MANAGEMENT BUSINESS TRUST4,505,3630 00For
Delaware/Macquarie4,081,5080 00For
Hood River Capital Management LLC3,914,6440 00For
Charles Schwab3,743,2430 00For
NORTHERN LIGHTS FUND TRUST II3,280,1950 00For
Palo Alto Investors LP3,032,2090 00For
PRINCIPAL GLOBAL INVESTORS3,010,0850 00For
State Street2,968,2171,456 00For
Principal2,095,3110 00For
Soleus Capital Management, L.P.1,906,9620 00For
Northern Trust1,371,3970 00For
BANK OF AMERICA NA1,298,1110 00For
C WorldWide Asset Management Fondsmaeglerselskab A/S01,260,000 00Against
RICE HALL JAMES & ASSOCIATES, LLC1,124,1950 00For
APIS CAPITAL ADVISORS, LLC1,098,1300 00For
Nuveen836,0180 00For
TIAA817,1170 00For
UBS0774,375 00Against
PICTET ASSET MANAGEMENT SA705,3190 00For
MPM BioImpact LLC647,4920 00For

Showing the 25 largest of 258 asset managers. See all 258 in the interactive database.

2. To elect seven directors to serve until the 2026 Annual Meeting of Stockholders: Athena Countouriotis, M.D.

DIRECTOR ELECTIONSMajority of the votes cast: yes

Meeting held 2025-06-10.

Combines 2 wordings of this item as funds reported it.

57% Majority: yes · of votes cast

FOR 57%AGAINST 43%
FOR: 97,767,917AGAINST: 75,070,020

IOVANCE BIOTHERAPEUTICS INC.’s own tally for this item (“Elect Director: Dr. Countouriotis”): 97,767,917 for, 75,070,020 against, per its Form 8-K filed 2025-06-10 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 333,934,387 outstanding shares: 29% for, 22% against (51.8% of the company cast a for/against vote).

The 63 asset managers below cast 11% of the shares they voted on this item FOR (6,093,079 for, 48,604,029 against).

11%AGAINST 89%
FOR: 6,093,079 (11.1%)AGAINST: 48,604,029 (88.8%)ABSTAIN: 27,255 (0.0%)
Largest asset managers voting on “To elect seven directors to serve until the 2026 Annual Meeting of Stockholders: Athena Countouriotis, M.D.” at IOVANCE BIOTHERAPEUTICS INC., 2024-2025
Asset managerForAgainst AbstainWithheldVote
Vanguard10127,857,904 00Against
BlackRock07,151,892 00Against
Delaware/Macquarie04,081,508 00Against
NORTHERN LIGHTS FUND TRUST II3,280,1950 00For
T. Rowe Price02,430,276 00Against
Principal6112,094,700 00Against
Charles Schwab1,871,6040 00For
TIAA0817,117 00Against
Equitable0610,583 00Against
Fidelity0305,709 00Against
Manager Directed Portfolios302,8720 00For
Lincoln Financial0275,886 00Against
QUANTITATIVE MASTER SERIES LLC0270,099 00Against
State Street738269,003 00Against
Virtus0177,635 00Against
Global X162,1420 00For
PRINCIPAL VARIABLE CONTRACTS FUNDS INC0160,900 00Against
RMB INVESTORS TRUST0157,696 00Against
Guggenheim0150,408 00Against
John Hancock0147,607 00Against
Brighthouse0119,976 27,2550Against
Direxion Shares ETF Trust0145,798 00Against
ProShares0145,497 00Against
AIG/SunAmerica0140,283 00Against
Aberdeen131,8000 00For

Showing the 25 largest of 63 asset managers. See all 63 in the interactive database.

3. To elect seven directors to serve until the 2026 Annual Meeting of Stockholders: Frederick G. Vogt, Ph.D., J.D.

DIRECTOR ELECTIONSMajority of the votes cast: yes

Meeting held 2025-06-10.

Combines 2 wordings of this item as funds reported it.

95% Majority: yes · of votes cast

FOR 95%
FOR: 165,079,137AGAINST: 8,467,205

IOVANCE BIOTHERAPEUTICS INC.’s own tally for this item (“Elect Director: Dr. Vogt”): 165,079,137 for, 8,467,205 against, per its Form 8-K filed 2025-06-10 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 333,934,387 outstanding shares: 49.4% for, 3% against (52.0% of the company cast a for/against vote).

The 63 asset managers below cast 99.9% of the shares they voted on this item FOR (54,697,108 for, 0 against).

FOR 99.9%
FOR: 54,697,108 (100.0%)AGAINST: 0 (0.0%)ABSTAIN: 27,255 (0.0%)
Largest asset managers voting on “To elect seven directors to serve until the 2026 Annual Meeting of Stockholders: Frederick G. Vogt, Ph.D., J.D” at IOVANCE BIOTHERAPEUTICS INC., 2024-2025
Asset managerForAgainst AbstainWithheldVote
Vanguard27,858,0050 00For
BlackRock7,151,8920 00For
Delaware/Macquarie4,081,5080 00For
NORTHERN LIGHTS FUND TRUST II3,280,1950 00For
T. Rowe Price2,430,2760 00For
Principal2,095,3110 00For
Charles Schwab1,871,6040 00For
TIAA817,1170 00For
Equitable610,5830 00For
Fidelity305,7090 00For
Manager Directed Portfolios302,8720 00For
Lincoln Financial275,8860 00For
QUANTITATIVE MASTER SERIES LLC270,0990 00For
State Street269,7410 00For
Virtus177,6350 00For
Global X162,1420 00For
PRINCIPAL VARIABLE CONTRACTS FUNDS INC160,9000 00For
RMB INVESTORS TRUST157,6960 00For
Guggenheim150,4080 00For
John Hancock147,6070 00For
Brighthouse119,9760 27,2550For
Direxion Shares ETF Trust145,7980 00For
ProShares145,4970 00For
AIG/SunAmerica140,2830 00For
Aberdeen131,8000 00For

Showing the 25 largest of 63 asset managers. See all 63 in the interactive database.

4. To elect seven directors to serve until the 2026 Annual Meeting of Stockholders: lain Dukes, D. Phil.

DIRECTOR ELECTIONSMajority of the votes cast: yes

Meeting held 2025-06-10.

Combines 3 wordings of this item as funds reported it.

82% Majority: yes · of votes cast

FOR 82%AGAINST 18%
FOR: 142,089,795AGAINST: 30,706,393

IOVANCE BIOTHERAPEUTICS INC.’s own tally for this item (“Elect Director: Dr. Dukes”): 142,089,795 for, 30,706,393 against, per its Form 8-K filed 2025-06-10 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 333,934,387 outstanding shares: 43% for, 9% against (51.7% of the company cast a for/against vote).

The 63 asset managers below cast 77% of the shares they voted on this item FOR (41,893,482 for, 12,803,626 against).

FOR 77%AGAINST 23%
FOR: 41,893,482 (76.6%)AGAINST: 12,803,626 (23.4%)ABSTAIN: 27,255 (0.0%)
Largest asset managers voting on “To elect seven directors to serve until the 2026 Annual Meeting of Stockholders: lain Dukes, D. Phil.” at IOVANCE BIOTHERAPEUTICS INC., 2024-2025
Asset managerForAgainst AbstainWithheldVote
Vanguard27,855,7912,214 00For
BlackRock408,1876,743,705 00Against
Delaware/Macquarie04,081,508 00Against
NORTHERN LIGHTS FUND TRUST II3,280,1950 00For
T. Rowe Price2,430,2760 00For
Principal2,095,3110 00For
Charles Schwab1,871,6040 00For
TIAA817,1170 00For
Equitable2,130608,453 00Against
Fidelity211,98993,720 00For
Manager Directed Portfolios302,8720 00For
Lincoln Financial75,186200,700 00Against
QUANTITATIVE MASTER SERIES LLC0270,099 00Against
State Street1,062268,679 00Against
Virtus177,6350 00For
Global X162,1420 00For
PRINCIPAL VARIABLE CONTRACTS FUNDS INC160,9000 00For
RMB INVESTORS TRUST157,6960 00For
Guggenheim150,4080 00For
John Hancock147,6070 00For
Brighthouse119,9760 27,2550For
Direxion Shares ETF Trust145,7980 00For
ProShares145,4970 00For
AIG/SunAmerica140,2830 00For
Aberdeen131,8000 00For

Showing the 25 largest of 63 asset managers. See all 63 in the interactive database.

5. To elect seven directors to serve until the 2026 Annual Meeting of Stockholders: Michael Weiser, M.D., Ph.D.

DIRECTOR ELECTIONSMajority of the votes cast: yes

Meeting held 2025-06-10.

Combines 2 wordings of this item as funds reported it.

96% Majority: yes · of votes cast

FOR 96%
FOR: 165,295,535AGAINST: 7,540,940

IOVANCE BIOTHERAPEUTICS INC.’s own tally for this item (“Elect Director: Dr. Weiser”): 165,295,535 for, 7,540,940 against, per its Form 8-K filed 2025-06-10 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 333,934,387 outstanding shares: 49.5% for, 2% against (51.8% of the company cast a for/against vote).

The 63 asset managers below cast 99.6% of the shares they voted on this item FOR (54,511,283 for, 185,825 against).

FOR 99.6%
FOR: 54,511,283 (99.6%)AGAINST: 185,825 (0.3%)ABSTAIN: 27,255 (0.0%)
Largest asset managers voting on “To elect seven directors to serve until the 2026 Annual Meeting of Stockholders: Michael Weiser, M.D., Ph.D.” at IOVANCE BIOTHERAPEUTICS INC., 2024-2025
Asset managerForAgainst AbstainWithheldVote
Vanguard27,855,7912,214 00For
BlackRock7,151,8920 00For
Delaware/Macquarie4,081,5080 00For
NORTHERN LIGHTS FUND TRUST II3,280,1950 00For
T. Rowe Price2,430,2760 00For
Principal2,095,3110 00For
Charles Schwab1,871,6040 00For
TIAA817,1170 00For
Equitable610,5830 00For
Fidelity305,7090 00For
Manager Directed Portfolios302,8720 00For
Lincoln Financial275,8860 00For
QUANTITATIVE MASTER SERIES LLC270,0990 00For
State Street269,7410 00For
Virtus177,6350 00For
Global X162,1420 00For
PRINCIPAL VARIABLE CONTRACTS FUNDS INC160,9000 00For
RMB INVESTORS TRUST157,6960 00For
Guggenheim150,4080 00For
John Hancock147,6070 00For
Brighthouse119,9760 27,2550For
Direxion Shares ETF Trust145,7980 00For
ProShares145,4970 00For
AIG/SunAmerica140,2830 00For
Aberdeen131,8000 00For

Showing the 25 largest of 63 asset managers. See all 63 in the interactive database.

6. To elect seven directors to serve until the 2026 Annual Meeting of Stockholders: Ryan Maynard

DIRECTOR ELECTIONSMajority of the votes cast: yes

Meeting held 2025-06-10.

Combines 2 wordings of this item as funds reported it.

96% Majority: yes · of votes cast

FOR 96%
FOR: 166,367,869AGAINST: 6,453,538

IOVANCE BIOTHERAPEUTICS INC.’s own tally for this item (“Elect Director: Mr. Maynard”): 166,367,869 for, 6,453,538 against, per its Form 8-K filed 2025-06-10 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 333,934,387 outstanding shares: 49.8% for, 2% against (51.8% of the company cast a for/against vote).

The 63 asset managers below cast 99.7% of the shares they voted on this item FOR (54,542,338 for, 154,770 against).

FOR 99.6%
FOR: 54,542,338 (99.7%)AGAINST: 154,770 (0.3%)ABSTAIN: 27,255 (0.0%)
Largest asset managers voting on “To elect seven directors to serve until the 2026 Annual Meeting of Stockholders: Ryan Maynard” at IOVANCE BIOTHERAPEUTICS INC., 2024-2025
Asset managerForAgainst AbstainWithheldVote
Vanguard27,858,0050 00For
BlackRock7,151,8920 00For
Delaware/Macquarie4,081,5080 00For
NORTHERN LIGHTS FUND TRUST II3,280,1950 00For
T. Rowe Price2,430,2760 00For
Principal2,095,3110 00For
Charles Schwab1,871,6040 00For
TIAA817,1170 00For
Equitable610,5830 00For
Fidelity305,7090 00For
Manager Directed Portfolios302,8720 00For
Lincoln Financial275,8860 00For
QUANTITATIVE MASTER SERIES LLC270,0990 00For
State Street269,7410 00For
Virtus177,6350 00For
Global X162,1420 00For
PRINCIPAL VARIABLE CONTRACTS FUNDS INC160,9000 00For
RMB INVESTORS TRUST157,6960 00For
Guggenheim150,4080 00For
John Hancock147,6070 00For
Brighthouse119,9760 27,2550For
Direxion Shares ETF Trust145,7980 00For
ProShares145,4970 00For
AIG/SunAmerica140,2830 00For
Aberdeen131,8000 00For

Showing the 25 largest of 63 asset managers. See all 63 in the interactive database.

7. To elect seven directors to serve until the 2026 Annual Meeting of Stockholders: Wayne P. Rothbaum

DIRECTOR ELECTIONSMajority of the votes cast: yes

Meeting held 2025-06-10.

Combines 2 wordings of this item as funds reported it.

97% Majority: yes · of votes cast

FOR 97%
FOR: 166,890,379AGAINST: 6,038,284

IOVANCE BIOTHERAPEUTICS INC.’s own tally for this item (“Elect Director: Mr. Rothbaum”): 166,890,379 for, 6,038,284 against, per its Form 8-K filed 2025-06-10 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 333,934,387 outstanding shares: 49.9% for, 2% against (51.8% of the company cast a for/against vote).

The 63 asset managers below cast 99.7% of the shares they voted on this item FOR (54,542,338 for, 154,770 against).

FOR 99.6%
FOR: 54,542,338 (99.7%)AGAINST: 154,770 (0.3%)ABSTAIN: 27,255 (0.0%)
Largest asset managers voting on “To elect seven directors to serve until the 2026 Annual Meeting of Stockholders: Wayne P. Rothbaum” at IOVANCE BIOTHERAPEUTICS INC., 2024-2025
Asset managerForAgainst AbstainWithheldVote
Vanguard27,858,0050 00For
BlackRock7,151,8920 00For
Delaware/Macquarie4,081,5080 00For
NORTHERN LIGHTS FUND TRUST II3,280,1950 00For
T. Rowe Price2,430,2760 00For
Principal2,095,3110 00For
Charles Schwab1,871,6040 00For
TIAA817,1170 00For
Equitable610,5830 00For
Fidelity305,7090 00For
Manager Directed Portfolios302,8720 00For
Lincoln Financial275,8860 00For
QUANTITATIVE MASTER SERIES LLC270,0990 00For
State Street269,7410 00For
Virtus177,6350 00For
Global X162,1420 00For
PRINCIPAL VARIABLE CONTRACTS FUNDS INC160,9000 00For
RMB INVESTORS TRUST157,6960 00For
Guggenheim150,4080 00For
John Hancock147,6070 00For
Brighthouse119,9760 27,2550For
Direxion Shares ETF Trust145,7980 00For
ProShares145,4970 00For
AIG/SunAmerica140,2830 00For
Aberdeen131,8000 00For

Showing the 25 largest of 63 asset managers. See all 63 in the interactive database.

8. To elect seven directors to serve until the 2026 Annual Meeting of Stockholders: Wendy Yarno

DIRECTOR ELECTIONSMajority of the votes cast: yes

Meeting held 2025-06-10.

Combines 2 wordings of this item as funds reported it.

97% Majority: yes · of votes cast

FOR 97%
FOR: 166,781,324AGAINST: 5,674,432

IOVANCE BIOTHERAPEUTICS INC.’s own tally for this item (“Elect Director: Ms. Yarno”): 166,781,324 for, 5,674,432 against, per its Form 8-K filed 2025-06-10 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 333,934,387 outstanding shares: 49.9% for, 2% against (51.6% of the company cast a for/against vote).

The 63 asset managers below cast 99.9% of the shares they voted on this item FOR (54,697,108 for, 0 against).

FOR 99.9%
FOR: 54,697,108 (100.0%)AGAINST: 0 (0.0%)ABSTAIN: 27,255 (0.0%)
Largest asset managers voting on “To elect seven directors to serve until the 2026 Annual Meeting of Stockholders: Wendy Yarno” at IOVANCE BIOTHERAPEUTICS INC., 2024-2025
Asset managerForAgainst AbstainWithheldVote
Vanguard27,858,0050 00For
BlackRock7,151,8920 00For
Delaware/Macquarie4,081,5080 00For
NORTHERN LIGHTS FUND TRUST II3,280,1950 00For
T. Rowe Price2,430,2760 00For
Principal2,095,3110 00For
Charles Schwab1,871,6040 00For
TIAA817,1170 00For
Equitable610,5830 00For
Fidelity305,7090 00For
Manager Directed Portfolios302,8720 00For
Lincoln Financial275,8860 00For
QUANTITATIVE MASTER SERIES LLC270,0990 00For
State Street269,7410 00For
Virtus177,6350 00For
Global X162,1420 00For
PRINCIPAL VARIABLE CONTRACTS FUNDS INC160,9000 00For
RMB INVESTORS TRUST157,6960 00For
Guggenheim150,4080 00For
John Hancock147,6070 00For
Brighthouse119,9760 27,2550For
Direxion Shares ETF Trust145,7980 00For
ProShares145,4970 00For
AIG/SunAmerica140,2830 00For
Aberdeen131,8000 00For

Showing the 25 largest of 63 asset managers. See all 63 in the interactive database.

9. To approve an amendment to our 2018 Equity Incentive Plan to increase the number of shares of the Company's common stock authorized for issuance thereunder by 12,500,000 shares; and

COMPENSATION

Meeting held 2025-06-10.

Combines 2 wordings of this item as funds reported it.

99.8% fund support · no official result

FOR 99.8%

The 63 asset managers below cast 99.8% of the shares they voted on this item FOR (54,619,134 for, 77,974 against).

FOR: 54,619,134 (99.8%)AGAINST: 77,974 (0.1%)ABSTAIN: 27,255 (0.0%)
Largest asset managers voting on “To approve an amendment to our 2018 Equity Incentive Plan to increase the number of shares of the Company's co” at IOVANCE BIOTHERAPEUTICS INC., 2024-2025
Asset managerForAgainst AbstainWithheldVote
Vanguard27,858,0050 00For
BlackRock7,151,8920 00For
Delaware/Macquarie4,081,5080 00For
NORTHERN LIGHTS FUND TRUST II3,280,1950 00For
T. Rowe Price2,430,2760 00For
Principal2,095,3110 00For
Charles Schwab1,871,6040 00For
TIAA817,1170 00For
Equitable610,5830 00For
Fidelity305,7090 00For
Manager Directed Portfolios302,8720 00For
Lincoln Financial275,8860 00For
QUANTITATIVE MASTER SERIES LLC270,0990 00For
State Street269,7365 00For
Virtus177,6350 00For
Global X162,1420 00For
PRINCIPAL VARIABLE CONTRACTS FUNDS INC160,9000 00For
RMB INVESTORS TRUST157,6960 00For
Guggenheim150,4080 00For
John Hancock147,6070 00For
Brighthouse119,9760 27,2550For
Direxion Shares ETF Trust145,7980 00For
ProShares145,4970 00For
AIG/SunAmerica140,2830 00For
Aberdeen131,8000 00For

Showing the 25 largest of 63 asset managers. See all 63 in the interactive database.

10. TO APPROVE AN AMENDMENT TO OUR 2020 EMPLOYEE STOCK PURCHASE PLAN TO INCREASE THE NUMBER OF SHARES OF THE COMPANY'S COMMON STOCK AUTHORIZED FOR ISSUANCE THEREUNDER BY 1,000,000 SHARES.

COMPENSATION

Meeting held 2025-06-10.

99.9% fund support · no official result

FOR 99.9%

The 63 asset managers below cast 99.9% of the shares they voted on this item FOR (54,697,108 for, 27,255 against).

FOR: 54,697,108 (100.0%)AGAINST: 27,255 (0.0%)ABSTAIN: 0 (0.0%)
Largest asset managers voting on “TO APPROVE AN AMENDMENT TO OUR 2020 EMPLOYEE STOCK PURCHASE PLAN TO INCREASE THE NUMBER OF SHARES OF THE COMPA” at IOVANCE BIOTHERAPEUTICS INC., 2024-2025
Asset managerForAgainst AbstainWithheldVote
Vanguard27,858,0050 00For
BlackRock7,151,8920 00For
Delaware/Macquarie4,081,5080 00For
NORTHERN LIGHTS FUND TRUST II3,280,1950 00For
T. Rowe Price2,430,2760 00For
Principal2,095,3110 00For
Charles Schwab1,871,6040 00For
TIAA817,1170 00For
Equitable610,5830 00For
Fidelity305,7090 00For
Manager Directed Portfolios302,8720 00For
Lincoln Financial275,8860 00For
QUANTITATIVE MASTER SERIES LLC270,0990 00For
State Street269,7410 00For
Virtus177,6350 00For
Global X162,1420 00For
PRINCIPAL VARIABLE CONTRACTS FUNDS INC160,9000 00For
RMB INVESTORS TRUST157,6960 00For
Guggenheim150,4080 00For
John Hancock147,6070 00For
Brighthouse119,97627,255 00For
Direxion Shares ETF Trust145,7980 00For
ProShares145,4970 00For
AIG/SunAmerica140,2830 00For
Aberdeen131,8000 00For

Showing the 25 largest of 63 asset managers. See all 63 in the interactive database.

11. To ratify the appointment of Ernst & Young LLP as our independent registered public accounting firm for our fiscal year ending December 31, 2025;

AUDIT-RELATED

Meeting held 2025-06-10.

Combines 2 wordings of this item as funds reported it.

99.9% fund support · no official result

FOR 99.9%

The 63 asset managers below cast 99.9% of the shares they voted on this item FOR (54,697,108 for, 0 against).

FOR: 54,697,108 (100.0%)AGAINST: 0 (0.0%)ABSTAIN: 27,255 (0.0%)
Largest asset managers voting on “To ratify the appointment of Ernst & Young LLP as our independent registered public accounting firm for our fi” at IOVANCE BIOTHERAPEUTICS INC., 2024-2025
Asset managerForAgainst AbstainWithheldVote
Vanguard27,858,0050 00For
BlackRock7,151,8920 00For
Delaware/Macquarie4,081,5080 00For
NORTHERN LIGHTS FUND TRUST II3,280,1950 00For
T. Rowe Price2,430,2760 00For
Principal2,095,3110 00For
Charles Schwab1,871,6040 00For
TIAA817,1170 00For
Equitable610,5830 00For
Fidelity305,7090 00For
Manager Directed Portfolios302,8720 00For
Lincoln Financial275,8860 00For
QUANTITATIVE MASTER SERIES LLC270,0990 00For
State Street269,7410 00For
Virtus177,6350 00For
Global X162,1420 00For
PRINCIPAL VARIABLE CONTRACTS FUNDS INC160,9000 00For
RMB INVESTORS TRUST157,6960 00For
Guggenheim150,4080 00For
John Hancock147,6070 00For
Brighthouse119,9760 27,2550For
Direxion Shares ETF Trust145,7980 00For
ProShares145,4970 00For
AIG/SunAmerica140,2830 00For
Aberdeen131,8000 00For

Showing the 25 largest of 63 asset managers. See all 63 in the interactive database.

12. Advisory Vote to Ratify Named Executive Officers' Compensation

SECTION 14A SAY-ON-PAY VOTESCOMPENSATION

Meeting held 2025-06-10.

99.9% fund support · no official result

FOR 99.9%

The 4 asset managers below cast 99.9% of the shares they voted on this item FOR (1,241,815 for, 5 against).

FOR: 1,241,815 (100.0%)AGAINST: 5 (0.0%)
Largest asset managers voting on “Advisory Vote to Ratify Named Executive Officers' Compensation” at IOVANCE BIOTHERAPEUTICS INC., 2024-2025
Asset managerForAgainst AbstainWithheldVote
JPMorgan1,241,5470 00For
Coyle Financial Counsel LLC1340 00For
SIERRA SUMMIT ADVISORS LLC1340 00For
MILLER HOWARD INVESTMENTS INC /NY05 00Against

13. 14A Executive Compensation

SECTION 14A SAY-ON-PAY VOTES

Meeting held 2025-06-10.

100% fund support · no official result

FOR 100%

The 2 asset managers below cast 100% of the shares they voted on this item FOR (817 for, 0 against).

FOR: 817 (100.0%)
Largest asset managers voting on “14A Executive Compensation” at IOVANCE BIOTHERAPEUTICS INC., 2024-2025
Asset managerForAgainst AbstainWithheldVote
Focus Partners Wealth5440 00For
VOISARD ASSET MANAGEMENT GROUP, INC.2730 00For

14. To approve, by non-binding advisory vote, the compensation of our named executive officers.

SECTION 14A SAY-ON-PAY VOTES

Meeting held 2024-06-11 (outside the 2024-2025 season's 1 July to 30 June window; reported in this season's filings).

Combines 2 wordings of this item as funds reported it.

0% fund support · no official result

AGAINST 100%

The 2 asset managers below cast 0% of the shares they voted on this item FOR (0 for, 230 against).

AGAINST: 230 (100.0%)
Largest asset managers voting on “To approve, by non-binding advisory vote, the compensation of our named executive officers.” at IOVANCE BIOTHERAPEUTICS INC., 2024-2025
Asset managerForAgainst AbstainWithheldVote
COLDSTREAM CAPITAL MANAGEMENT INC0230 00Against
Echo45 Advisors LLC00 00--

Largest IOVANCE BIOTHERAPEUTICS INC. shareholders voting in 2024-2025

Ranked by the number of IOVANCE BIOTHERAPEUTICS INC. shares each manager voted on the most widely held ballot item of the 2024-2025 meeting, shown as a share of the 333,934,387 shares outstanding at the time of that meeting.

Top IOVANCE BIOTHERAPEUTICS INC. shareholders by shares voted, 2024-2025
#Asset manager % of shares outstanding
1Vanguard 8.57%
2MHR FUND MANAGEMENT LLC 7.31%
3BlackRock 3.96%
4Invenomic Capital Management LP 1.97%
5T. Rowe Price 1.75%
6MACQUARIE INVESTMENT MANAGEMENT BUSINESS TRUST 1.35%
7Delaware/Macquarie 1.22%
8Hood River Capital Management LLC 1.17%
9Charles Schwab 1.12%
10NORTHERN LIGHTS FUND TRUST II 0.98%

Reported IOVANCE BIOTHERAPEUTICS INC. ownership

Positions disclosed to the SEC on Schedules 13D and 13G, Form 13F and the company’s own proxy statement (DEF 14A).

IOVANCE BIOTHERAPEUTICS INC. beneficial owners on record for the 2024-2025 proxy season
Holder % outstanding Disclosure
New York, NY 8.98% DEF14A
Wayne Rothbaum 8.98% DEF14A
Vanguard Group 8.32% 13F
BlackRock 7.28% 13F
Malvern, PA 6.83% DEF14A
State Street 3.31% 13F
Geode Capital 1.79% 13F
Goldman Sachs 1.67% 13F
Morgan Stanley 1.20% 13F
Renaissance Technologies 1.05% 13F

Percentages above are of 333,934,387 shares outstanding, as reported by IOVANCE BIOTHERAPEUTICS INC. on its Form 10-Q dated 2025-03-31 (see the filing on EDGAR). This is the count contemporaneous with the 2024-2025 meeting, so the percentages are the ones that were true then, not ones restated against today’s share count.

About this page

Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered investment companies and institutional managers disclose how they voted every proxy, and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from IOVANCE BIOTHERAPEUTICS INC.’s 10-Q dated 2025-03-31. This page is a static snapshot rebuilt weekly on 04 October 2026; a live search always shows the current data.

At IOVANCE BIOTHERAPEUTICS INC.'s shareholder meeting held 2025-06-10, in the 2024-2025 proxy season, 270 asset managers reported how they voted in their SEC Form N-PX filings, covering 2,323 separate fund positions. Their filings are grouped here into 14 reported items; because filers word the same ballot item differently, that can be more than the number of items on the ballot. IOVANCE BIOTHERAPEUTICS INC.'s own Form 8-K tally for this meeting is published below, but no row in it could be matched to the most widely held item, so this page states no certified outcome for that item. On that item — To approve, by non-binding advisory vote, the compensation of our named executive officers; — the reporting funds cast 97% of the shares they voted in favour (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side). That is the aggregate of those managers' own N-PX disclosures, not the company's certified result, and the funds are a subset of all shareholders.

IOVANCE BIOTHERAPEUTICS INC. proxy season coverage: 2023-2024 · 2024-2025 (this page) · 2025-2026.